Abstract: Thiochromanoylpyrazolone derivatives of the formula I where: A is an unsubstituted or substituted, saturated or unsaturated alkyl chain; R1 is cyano, thiocyanato, nitro, OR4, SR5, SOR6, S02R6, ONR6NR7, ON═CR6R8, NR9R10, P(O)R11R12, P(S)R11R12, COR, CO2R6, unsubstituted or substituted phenyl or heterocyclyl; R2 is alkyl, haloalkyl, alkoxy or haloalkoxy; R3 is hydrogen, alkyl or halogen; X is oxygen, sulfur, S═O, S(═O)2, CR13R14, C═O or C═NR15; m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; R16 is substituted pyrazol-4-yl-carbonyl or substituted (4,5-dihydro-5-oxo-pyrazol-4-yl)methylidene; and their agriculturally useful salts; Processes for preparing the thiochromanoylpyrazolone derivatives, compositions comprising them, and the use of these derivatives or of the compositions comprising them for controlling undesirable plants are described.

Abstract: The invention relates to novel 1-arylpyrazole oxime derivatives, of general formula (I) or (I bis) These compounds are found to be generally safe systemic insecticides for control of arthropod, nematode, helminth or protozoan pests including compositions and derivatives thereof.

Abstract: Described are novel photochromic 2H-naphtho[1,2-b]pyran compounds essentially characterized by having two adjacent moderate to strong electron donor substituents at the 8 and 9 positions or a fused heterocyclic group formed by the substituents coming together, weak to moderate electron donors at the 2 position and a rating of at least 80 in the Relative &Dgr;OD at Saturation Test. The compounds also have certain substituents at the 5 position and optionally at the 6 position of the naphtho portion of the compound. These compounds may be represented by the following graphic formula: Also described are polymeric organic host materials that contain or that are coated with such compounds. Optically clear articles such as ophthalmic lenses or adjacent plastic transparencies that incorporate the novel naphthopyran compounds or combinations thereof with complementary photochromic compounds, e.g.

Abstract: The invention described novel compounds of formula wherein the general symbols are as defined in claim 1, as stabilizers for protecting organic materials, in particular polymers and lubricants, against thermal, oxidative or light-induced degradation.

Abstract: A composition comprising (S)-5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylsulfinylpyrazole and (R)-5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylsulfinylpyrazole, enantiomerically enriched in the (S)-enantiomer.

Abstract: This invention relates to the compound N-[4-(3-chloro4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide that is an irreversible inhibitor of tyrosine kinases. This invention also relates to a method of treating cancer, atherosclerosis, restenosis, endometriosis, and psoriasis using the compound N-[4-(3-chloro4-fluoro-phenylamino)-7-(3-morpholin4-yl-propoxy)-quinazolin-6-yl]-acrylamide, and to a pharmaceutical composition that comprises the compound N-[4-(3-chloro4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide.

Abstract: This invention relates to a novel process of preparing selected 5-substituted pyrazoles useful as p38 kinase and COX-2 inhibitors.

Abstract: Compounds of the formula I in which R1 is C1-C4alkyl; R2 is cyano or NH2C(S)—; R3 is hydrogen, C1-C4alkyl, C1-C4haloalkyl, C3- or C4alkenyl, C3- or C4alkynyl, C3-C8haloalkenyl, NC—CH2—, HOC(O)—CH2— or C1-C4alkoxy-C(O)—CH2—; W is a group  and R4 to R6, R60, R61, R70, X1, X2, n1 and A1—B1 are as defined in claim 1, and the pyrazole N-oxide, agronomically acceptable salts and stereomers of these compounds of the formula I, with the exclusion of the compound of the formula  have good selective herbicidal properties when used pre- and post-emergence. The preparation of these compounds and their use as herbicidally active ingredients are described.

Abstract: A three stage process for producing propylene oxide from propylene, oxygen, and hydrogen. The first reaction step is the oxidation of isopropanol/water with molecular oxygen in a reaction-distillation column (approx. 500 psi and 350° F.), to produce hydrogen peroxide and acetone. The column is configured with an upper high liquid holdup reaction zone and a lower short residence time stripping zone. Inert gas circulating through the column effects separation of the hydrogen peroxide as part of the bottoms fraction and acetone as part of the distillate fraction. The liquid part of the distillate fraction comprising acetone, isopropanol and water is then reacted with hydrogen (second reaction step) under reactive-distillation conditions to convert the contained acetone back to isopropanol for subsequent recycle to the first reaction step. The third reaction step is the epoxidation of propylene (in stoichiometric excess) with the hydrogen peroxide solution in the presence of a titanium silicalite catalyst.

Abstract: Compounds of the following formula (I) and pharmaceutically acceptable esters and salts thereof: Ar is a phenyl group which may optionally be substituted by from 1 to 3 substituents selected from the group consisting of halogen atoms and trifluoromethyl groups. The compounds (and pharmaceutically acceptable esters and salts thereof) have excellent antifungal activity.

Abstract: A 1-aryl-3-cyano-5-(het)arylalkylaminopyrazole derivative represented by the general formula (1): process of making, intermediate thereof and pesticide therewith.

Abstract: Novel calcilytic compounds are provided.

Abstract: Disclosed are novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Abstract: Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, n and p are as defined here. In a specific embodiment, the compounds are selective modulators for Er-&bgr; over ER-&agr;. Methods are also disclosed for modulating ER-&bgr; in cells and/or tissues expressing the same, including cells and/or tissues that preferentially express ER-&bgr;. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.

Abstract: A compound of the formula wherein R1 is C1-3 alkyl optionally substituted with one or more fluorines; R2 is CH2OCH3 or 2 or 3-tetrahydrofuranyl; R3 is a pyrazole, imidazole or isoxazole group of partial formula (A), (B) or (C)  R4 is C1-3 alkyl; and R5 and R6, which may be the same or different, each represents C1-3 alkyl, halogen, CF3 or CN; or a pharmaceutically-acceptable salt thereof.

Abstract: The invention relates to a method for the production of 1-substituted 5-hydroxypyrazoles of formula (I) wherein R1 is C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkinyl, C3-C6-cycloalkyl or C1-C4-alkoxy, whereby these groups can be substituted by halogen, C1-C4-alkoxy, phenoxy, C1-C6-alkoxycarbonyl, C1-C6-alkylthiocarbonyl or a cyclic ring system with 3-14 ring atoms, by reacting a) an alkylvinylether of general formula (III) wherein R2 is C1-C6-alkyl or C3-C6-cycloalkyl, with phosgene (IVa), “diphosgene” (IVb) or “triphosgene” (IVc) to form acid chlorides of formula (V), b) transforming said acid chlorides by eliminating hydrogen chloride into the corresponding 3-alkoxyacrylic acid chloride of formula (VI) and c) reacting said acid chloride with hydrazines of formula (VII) wherein R1 has the above cited meaning, to form 5-hydroxypyrazoles of formula (I).

Abstract: Disclosed are novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Abstract: Disclosed are novel aromatic heterocyclic compounds of the formula (I) wherein Ar1, Ar2, L, Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Abstract: A compound of the formula (I): wherein: R1 is chlorine, difluoromethyl, trifluoromethyl or cyano; and R2is a group having the formula:  wherein: X is halogen, cyano, nitro or amino; Y1 is lower alkyl or lower alkoxy; and Z is halogen; or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are novel substituted pyrroles having the formula These compounds and their pharmaceutically acceptable salts are suitable for administration to patients as continuous infusion solution and are useful in the treatment and/or control of cell proliferative disorders, in particular cancer. Also disclosed are pharmaceutical compositions containing the foregoing compounds and methods for the treatment and/or control of cancer.